Efficacy and Safety of Symbicort Turbuhaler 160/4.5 microg/Inhalation, Two Inhalations Twice Daily Plus as-Needed Compared With Seretide Diskus 50/500 microg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation as-Needed - a 6-Month, Randomised, Double-Blind, Parallel-Group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD).

Trial Profile

Efficacy and Safety of Symbicort Turbuhaler 160/4.5 microg/Inhalation, Two Inhalations Twice Daily Plus as-Needed Compared With Seretide Diskus 50/500 microg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation as-Needed - a 6-Month, Randomised, Double-Blind, Parallel-Group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD).

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Salmeterol/fluticasone propionate (Primary) ; Terbutaline (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms AHEAD
  • Sponsors AstraZeneca
  • Most Recent Events

    • 22 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top